The treatment landscape of advanced angiosarcoma in Asia—A multi‐national collaboration from the Asian Sarcoma Consortium

• DOI: 10.1111/cas.14793
• Publication Date: 2021-01-04T04:24:22Z
• Authors: Tom Wei‐Wu Chen; Angela Pang; Mark E. Puhaindran; Myo Myint Maw; Herbert H. Loong; Virote Sriuranpong; Chih‐Chi Chang; Siyamol Mingmalairak; Takeshi Hirose; Makoto Endo; Akira Kawai; Mohamad Farid; Sze Huey Tan; Wei Lin Goh; Richard Quek; Jeffrey C. H. Chan; Alex K. C. Leung; Roger K. C. Ngan
• Keywords: Regimen

Abstract Angiosarcoma (AS) is a rare disease with dismal prognosis. The treatment landscape and prognostic factors for advanced AS, including locally advanced, unresectable, metastatic remain elusive. Asian Sarcoma Consortium an international collaborative effort to understand the sarcoma in Asia. We undertook retrospective chart review of AS patients seen 8 academic centers across Patients complete clinical, treatment, follow‐up data were enrolled. Overall, 276 included into this study; 84 (30%) had metachronous AS. median age was 67 y; primary sites cutaneous 55% visceral 45% patients. In total, 143 (52%) received at least 1 line systemic chemotherapy. most common first‐line chemotherapy regimen used paclitaxel (47.6%) followed by liposomal doxorubicin (19.6%). overall survival (OS) 7.8 mo. Significant OS > 65 (hazard ratio (HR) 1.54, P = .006), male gender (HR 1.39, .02), site 0.63, .004). progression‐free (PFS) 3.4 PFS single vs combination or regimens comparable. This study provides insight patterns Prognosis remains poor. Data from serve as benchmark future clinical design.